Tarsus Pharmaceuticals (TARS) Gross Margin (2021 - 2026)

Tarsus Pharmaceuticals' Gross Margin history runs 6 years deep, the most recent figure standing at 94.2% for Q1 2026.

• In Q1 2026, Gross Margin rose 85.0% year-over-year to 94.2%; the TTM figure through Mar 2026 stood at 93.48% (up 49.0% YoY), while the FY2025 annual figure was 93.2%, up 21.0% from the prior year.
• Gross Margin for Q1 2026 stood at 94.2%, up from 92.8% in the prior quarter.
• The five-year high for Gross Margin was 100.0% in Q1 2023, with the low at 79.85% in Q3 2023.
• The 5-year median for Gross Margin is 93.35% (2025), against an average of 93.12%.
• The sharpest annual moves came in 2022 and 2024: Gross Margin sank 1110 bps in 2022, then surged 1341 bps in 2024.
• Tarsus Pharmaceuticals' Gross Margin stood at 96.0% in 2022, then retreated by 6 bps to 90.7% in 2023, then increased by 2 bps to 92.58% in 2024, then gained by 0 bps to 92.8% in 2025, then gained by 2 bps to 94.2% in 2026.
• Business Quant data shows TARS's Gross Margin at 94.2% in Q1 2026, 92.8% in Q4 2025, and 93.0% in Q3 2025.